Login
Navigate Fool.com
Will ABT beat
the market?
Community Rating: 5 Stars: The Best

38.60 0.00 (0.00%)

REAL-TIME: Last trade at

company name or ticker

Recent Quotes

Company Photos
(Click to zoom)
1D 1W 3M 6M 1Y 2Y 3Y
Today's Open $38.73
Previous Close $38.60
Daily Range $38.52 - $38.82
52-Week Range $32.70 - $40.49
Market Cap $59.6B
P/E Ratio 25.91
Dividend (Yield) $0.88 (2.3%)
Ex-Dividend Date
Dividend Pay Date
04/11/14
05/15/14
Volume 3,557,576
Average Daily Volume 8,703,998
Current FY EPS $2.21

How do you think ABT
will perform against the market?

Top ABT Bull/Bear Pitches

 

DollarDaze100 (0)
Submitted November 11, 2011

Healthcare is roughly 16% of the GDP. The US model isn't the best but for right now the best companies can take advantage of the market, technology and demand. Keep an eye on this short/mid-term.

0 Replies Reply Report this Post
 

boiseidfool (< 20)
Submitted March 3, 2007

Idaho has filed a lawsuit that alleges Abbott Laboratories falsified wholesale drug prices and that the state has overpaid Medicaid reimbursements because of the manipulated drug prices. In the compl … More

3 Replies Reply Report this Post

News & Commentary Rss Feed

3 Things You Need to Watch For in Boston Scientific's Earnings

Boston Scientific's stock has surged as of late, but can shares keep up their rally with earnings season at hand?

Earnings Roundup: Baxter International Grows Ahead of Its Spin-Off

Sales at Baxter (BAX) biopharma and medical device businesses headed higher in the first quarter, suggesting a bright future for Baxter's planned separation of its biopharma and medical device business next year.

Noteworthy ETF Outflows: SSO, ABT, ACN, ACE

Earnings Roundup: Look Beyond Abbott Labs' Short-term Bumps

A recall in Abbott Labs (ABT) nutrition segment gave Mead Johnson (MJN) an edge, but that and other short-term hurdles shouldn't distract investors from the company's long-term opportunity.

Abbott Earnings Preview: Emerging Markets & New Products Likely To Drive Sales

Abbott’s Mixed Q1 Earnings Beat Estimates

Abbott Labs Earnings: Still Marking Time

Abbot's long-term potential is masked by its weak near-term growth.

RPT-UPDATE 2-Abbott beats profit forecast, but sales lag

UPDATE 1-Abbott Laboratories beats profit forecast, sales lags

Sector Update: Healthcare Shares Higher Pre-Market; St. Jude Q1 Earnings Top Street View

See More ABT News...

Sector

Healthcare

Industry

Drugs

Abbott Laboratories (ABT) Description

Principal business is the discovery, development, manufacture and sale of a broad and diversified line of health care products. Company has four segments: Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Vascular Products. Website: http://www.abbott.com/

Featured Broker Partners

Learn more about our new Fool ticker page!

Take a Tour
no thanks